Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search for
  Limits  Preview/Index  History  Clipboard  Details     
About Entrez

Text Version

Entrez PubMed
Help | FAQ

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries

Related Resources
Order Documents
NLM Catalog
NLM Gateway
Consumer Health
Clinical Alerts
PubMed Central


1: Obstet Gynecol Surv. 2004 Aug;59(8):564-6. Related Articles, Links
Click here to read 
Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.

Zeskind PS, Stephens LE.

Department of Pediatrics, Carolinas Medical Center, Charlotte, North Carolina; and the Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina.

The used of selective serotonin reuptake inhibitors (SSRIs) by depressed parturients has raised concern over possible teratogenic effects on the fetus. These drugs readily cross the placental barrier, exposing the fetus to increased serotonin levels early in development. This prospective study evaluated infant neurobehavior 14 to 39 hours after birth; all were normal-birth infants. Half the mothers were taking an SSRI. The users and nonusers were matched for cigarette smoking, maternal age, and socioeconomic status. Infants were monitored for behavior, startles, and tremulousness for 1 hour between feedings. Motor activity and heart rate variability (HRV) were recorded during a 15-minute sleep period. Behavioral assessment was based on the Neonatal Behavioral Assessment Scale. The SSRI-exposed infants had shorter gestational ages. They exhibited more motor activity and tremulousness than did unexposed infants and had fewer rhythms in HRV. They also had fewer changes in behavioral state and fewer such states. Peak behavioral state was lower in the exposed infants. These infants also had significantly more rapid-eye-movement sleep and tended to have more spontaneous startles and sudden arousals. After adjusting for gestational age, the only significant differences were in tremulousness and measures of state and sleep organization. Adjusted mean motor activity and spectral peaks in HRV no longer differed significantly between the SSRI-exposed and nonexposed infants. These findings do not support the view that using an SSRI during pregnancy has little effect on the developing fetus. It is possible that the observed changes in motor activity, startles, and HRV are mediated by the effects of SSRI exposure on gestational age.

PMID: 15277875 [PubMed - in process]